Everest Medicines Secures NMPA Approval for CARDAMYST, Expanding Cardiovascular Portfolio
Event summary
- Everest Medicines received NMPA approval for CARDAMYST® (etripamil) nasal spray for treating acute PSVT episodes in adults.
- CARDAMYST is the first self-administered treatment for PSVT in China, with 64% conversion to sinus rhythm within 30 minutes.
- The approval was supported by the global Phase III RAPID trial and the Phase III JX02002 study in China.
- Everest acquired the rights to develop, commercialize, and manufacture CARDAMYST in Greater China from CORXEL Pharmaceuticals in March 2026.
- CARDAMYST is also in Phase III development for atrial fibrillation with rapid ventricular response (AFib-RVR).
The big picture
Everest Medicines' NMPA approval for CARDAMYST marks a strategic milestone in expanding its cardiovascular portfolio, addressing a critical unmet need for self-administered treatments in China. The approval positions Everest to shift PSVT management from hospital-based care to patient-managed settings, potentially easing the burden on healthcare systems. With the drug also approved by the FDA in December 2025, Everest is well-positioned to capitalize on its commercialization expertise and proprietary mRNA platform to drive long-term growth in the cardiovascular sector.
What we're watching
- Commercialization Strategy
- How Everest Medicines will leverage its commercialization capabilities to accelerate the launch of CARDAMYST in China.
- Market Expansion
- Whether CARDAMYST can capture a significant share of the estimated 3 to 6 million PSVT patients in China.
- Pipeline Development
- The pace at which Everest Medicines advances CARDAMYST for other cardiovascular indications, such as AFib-RVR.